The FIND-CKD clinical trial app is designed to enable mobile clinicians to enter e-source during mobile clinical visits from their own mobile device. Access is restricted to registered and delegated mobile clinicians in possession of a valid activation code. ...
FIND-CKD: a random- ized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrology, Dialysis and Transplantation 2014; 2014 Jun 6; doi 10.1093/ndt/gfu201.I. C., MacdougallA. H., BockF., CarreraK.-U., ...
The FIND-CKD clinical trial app is designed to enable mobile clinicians to enter e-source during mobile clinical visits from their own mobile device. Access is restricted to registered and delegated mobile clinicians in possession of a valid activation code. ...
Design and Baseline Characteristics of the FIND-CKD Trial: Efficacy of Finerenone on Kidney Disease Progression in People with Non-Diabetic CKDdoi:10.1681/ASN.20233411S1678aHiddo J. HeerspinkUniversity Medical Center Groningen, Groningen, Netherlands;Rajiv Agarwal...
The article discusses the study "FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anemia," by I. C. Macdougall and colleagues in the June 2, 2014 issue of the journal "Nephrology Dialysis ...
Discussion FIND-CKD was the longest randomized trial of IV iron therapy to date. Its findings will address several unanswered questions regarding iron therapy to treat iron deficiency anaemia in patients with ND-CKD. It was also the first randomized trial to utilize both a high and low serum ...
Find-Ckd Study InvestigatorsOxford University PressMacdougall IC, Bock A, Carrera F, Eckardt KU, Gaillard C, Van Wyck D, Roubert B, Cushway T, Roger SD, FIND-CKD Study Investigators. The FIND- CKD study a randomized controlled trial of intravenous iron versus oral iron in non-dialysis ...
Amgen trial will evaluate impact of treating anemia on cardiovascular risks in patients with CKD, type 2 diabetes
were significantly fewer with ferric carboxymaltose than with oral iron (2.7% and 26.2%, respectively; P < 0.0001).We conclude that 1000 mg ferric carboxymaltose can be rapidly administered, is more effective and is better tolerated than oral iron for treatment of iron deficiency in ND-CKD ...
FIND-CKD: a randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemiaanaemiachronic kidney diseaseBackground The optimal iron therapy regimen in patients with non-dialysis-dependent chronic kidney disease (CKD) is unknown. ...